All News
Sarilumab is FDA Approved for PMR
Yesterday, the U.S. Food and Drug Administration (FDA) approved sarilumab (Kevzara) for the treatment of adults with active, refractory polymyalgia rheumatica (PMR), stipulating it is indicated in those patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
Read Article
Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments
d
MedPage Today
Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.
Read Article
Treat-to-Target Guidelines for GCA and PMR
The Annals of Rheumatic Disease has published updated multinational, treat-to-target (T2T) recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
Read Article
CorEvitas registry data shows H2H comparison of 369 CCP+ abatacept & 475 CCP+ tofacitinib treated patients showed equivalent drug responses (reduced CDAI or PRO's); b/tsDMARD naive pts had numerically better ABA response at 6 mos (P = 0.662) https://t.co/36jr7l2DKm https://t.co/PItYrvMUNV
Links:
Dr. John Cush RheumNow ( View Tweet)
Granulomatous Myositis? Back to Square One
Samuel Ng, MD, presents his poster at RWCS 2023.
https://t.co/7dcbUbRe8b https://t.co/9lobNJOkJd
Links:
Dr. John Cush RheumNow ( View Tweet)
While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/RtI9ulurB1 https://t.co/wMl5DOyGB6
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trials of Baricitinib Disappoint in SL
Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE.
https://t.co/JjouppdG8k https://t.co/SHATPuTIiP
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean study Neonatal/maternal outcomes w/ NSAIDs. 1.8 million pregn assoc w/ early preg NSAIDs exposure - incr risks for major congenital malformations (adjRR 1.14), low birth Wt (1.29) & maternal oligohydramnios (1.09); higher w/ COX-2i or NSAIDs>10d https://t.co/SaRrVOHOt9 https://t.co/b2YqUh91fK
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/kA9pTauvDP https://t.co/GGlyvQcyat
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out last week's podcast--we discuss interesting data on the risk of arthritis comes from a large NHANES study.
https://t.co/w5TNhH7a2f https://t.co/bkKDoWA0ft
Links:
Dr. John Cush RheumNow ( View Tweet)
Is it Lupus?
https://t.co/PIIFeeHVMf https://t.co/5fUfAAyFul
Links:
Dr. John Cush RheumNow ( View Tweet)
An Alternative Pain Protocol Following Knee Replacement Surgery
A study reports that a novel surgical pain management strategy following total knee arthroplasty (TKA), or total knee replacement, provided pain relief without opioids.
https://t.co/OMQ4Tjl8Yv https://t.co/Hu59WJohcN
Links:
Dr. John Cush RheumNow ( View Tweet)
We're less than 3 weeks out from RheumNow Live. Are you coming? We'll be hosting a variety of topic panels, including one focused on Spondyloarthritis Innovations. Join us!
https://t.co/AOJGKTss7Q https://t.co/7nCdgwO6Zh
Links:
Dr. John Cush RheumNow ( View Tweet)
VTE Options
QD Clinic - Lessons from the clinic, brought to you by https://t.co/4UQlqwujiR March 18 &19, 2023 - Dallas, TX
https://t.co/xmtC8fvYUa https://t.co/FX6o35qwFW
Dr. John Cush RheumNow ( View Tweet)
Study of 78 pt suspected of #GCA undergoing Temp. artery Bx and US. Nearly half (35) Dx w/ GCA. Both had similar sensitivities(69% and 63%, respectively), but specificity higher w/ biopsy (100% vs 79%). Compression sign had best diagnostic performance https://t.co/ATPtN8WZin https://t.co/1MIrmp45AX
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Molly's in trouble
https://t.co/dTSHHlsCVD https://t.co/Vo9ZSHo5JB
Links:
Dr. John Cush RheumNow ( View Tweet)
In #RA, Citrullination modulates antigen processing and presentation by exposing otherwise cryptic epitopes https://t.co/aciZe4KG6H https://t.co/i7twPvb5P4
Dr. John Cush RheumNow ( View Tweet)
The Late Edition (2.24.2023)
This week’s reviews on the news and events from RheumNow.
https://t.co/44soaEGm5c https://t.co/1sBmKjDImE
Links:
Dr. John Cush RheumNow ( View Tweet)
Drs Schett & Mackensen reported a case of refractory inflammatory myositis successfully treated with CD19 CAR T cells. 41yoM w/ +Jo-1, myositis, ILD, Raynauds, periorb edema, not responding to steroids, RTX, IVIG, tacrolimus, CTX https://t.co/x2ljxNdXVM https://t.co/bVmQ0law5H
Links:
Dr. John Cush RheumNow ( View Tweet)
Swedish registry of Axial SpA pregnancies, 1580 births (matched 1:10), saw improved Preg outcomes & incr biologic use. SpA pts had signif. incr in preterm (RR 1·43), preeclampsia (1·44), C-Sect (1·59), infant SIE (1·29) - Each decreased by annually 0.5% https://t.co/EAUwxNsgzH https://t.co/tmNi3dQtMK
Links:
Dr. John Cush RheumNow ( View Tweet)